Pharmacokinetics & Drug Delivery | Neuropharmacology & Psychopharmacology | Anterior Uveitis & Posterior Uveitis
Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis
Karina Julian, Beate-J Langner-Wegscheider, Anton Haas, Marc De Smet*
*Corresponding author: Marc De Smet
Retina & Inflammation Unit, Montchoisi Clinic, Lausanne, Switzerland
Department of Ophthalmology, University of Amsterdam, Amsterdam, Netherlands
F1000Posters 2012, 3: 428 (poster) [English]
Poster [722.91 KB] | Recommended by F1000Prime
Presented at
The Association for Research and Vision in Ophthalmology (ARVO) meeting 2012,
4 - 8 May 2012, 1181-D828
Jornadas Argentinas de Oftalmología (Argentine Council of Ophthalmology Conference) 2012,
17 - 19 May 2012, P000
Presumed tuberculous serpiginous-like choroiditis (Tb-SLC) is a specific entity for which tuberculosis has a key role. Even though tuberculostatics are the mainstay of treatment, those cases still progressing may require the use of immunosupressants. Intravitreal methotrexate (IVT MTX) is a potential therapy for them.
IVT MTX produced a rapid healing of choroidal lesions in all three eyes injected, with visual acuity improvement in the majority of them. No ocular/systemic adverse events were noted in relation to the drug or to the procedure.
More cases and longer follow up are needed to conclude about the definite role of IVT MTX in the management of the inflammatory component of Tb-SLC. This local approach has the potential of reducing the risk of systemic Tb reactivation.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
